- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01357941
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) (ROCITP2)
Prospective Study Assessing the Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism
Pregnant women with a prior history of venous thromboembolism (VTE) are at increased risk of recurrent VTE. Current guidelines assessing the role of prophylaxis in pregnant women with prior VTE are based primarily on expert opinion and the optimal clinical management strategy remains unclear.
This multicentre, prospective cohort study aims to test the following hypotheses:
- Antepartum prophylaxis with fixed-dose low molecular-weight heparin (LMWH) is safe, convenient and associated with an acceptably low risk of recurrent VTE in women with a single prior episode of VTE that was either unprovoked or associated with a minor transient risk factor. (Moderate risk cohort)
- Withholding antepartum prophylaxis is safe (recurrence risk <1%) in pregnant women with a single prior episode of VTE provoked by a major transient risk factor. (Low risk cohort)
All study patients will receive 6 weeks of postpartum prophylaxis.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Shannon M Bates, MD
- Número de teléfono: 73928 905-521-2100
- Correo electrónico: batesm@mcmaster.ca
Copia de seguridad de contactos de estudio
- Nombre: Nancy Lloyd, MSc
- Número de teléfono: 33269 905-522-1155
- Correo electrónico: lloydn@mcmaster.ca
Ubicaciones de estudio
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 4A6
- St. Joseph's Healthcare Hamilton
-
Contacto:
- James D Douketis, MD
- Número de teléfono: 36178 905-522-1155
- Correo electrónico: jdouket@mcmaster.ca
-
Investigador principal:
- James D Douketis, MD
-
Hamilton, Ontario, Canadá, L8N 3Z5
- McMaster University Medical Centre
-
Contacto:
- Shannon M Bates, MD
- Número de teléfono: 73928 905-521-2100
- Correo electrónico: batesm@mcmaster.ca
-
Investigador principal:
- Shannon M Bates, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Confirmed pregnancy (positive serum or urine)
- At least 18 years of age
- History of one prior episode of VTE consisting of DVT (diagnosed by compression ultrasonography [CUS] or venography) and/or PE (diagnosed by ventilation-perfusion [V/Q] lung scintigraphy, computed tomographic pulmonary angiography [CTPA], or traditional pulmonary angiography)
Exclusion Criteria:
- Ongoing need for therapeutic anticoagulation for prevention or treatment of cardioembolic stroke
- Known high-risk thrombophilia (specifically antithrombin deficiency, protein S deficiency, protein C deficiency, homozygosity for the factor V Leiden or prothrombin G20210A mutations, antiphospholipid antibody or compound abnormalities)
- VTE within 3 months of the current pregnancy
- Clinical risk factor for initial episode of VTE, if present, not resolved (excluding pregnancy)
- Known contraindication to anticoagulation (including active, uncontrolled bleeding or major bleed within the previous 4 weeks)
- For patients with prior unprovoked VTE, contraindication to LMWH (including allergy, HIT, impaired renal function, osteoporosis)
- Geographic or social factors precluding follow-up
- Inability or unwillingness to provide informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Prior VTE minor transient risk factor
Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
|
Prior VTE major transient risk factor
Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Symptomatic venous thromboembolism
Periodo de tiempo: antepartum period (expected average 7 months)
|
Symptomatic objectively confirmed recurrent VTE, including proximal DVT, non-fatal PE, and fatal PE during antepartum period
|
antepartum period (expected average 7 months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Symptomatic recurrent venous thromboembolism
Periodo de tiempo: antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic recurrent VTE antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic recurrent pulmonary embolism
Periodo de tiempo: antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic objectively confirmed recurrent PE antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
Thrombocytopenia or heparin-induced thrombocytopenia (HIT)
Periodo de tiempo: antepartum period (expected average 7 months)
|
Thrombocytopenia or HIT during antepartum period
|
antepartum period (expected average 7 months)
|
Symptomatic osteoporosis
Periodo de tiempo: antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic osteoporosis antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
Other complications
Periodo de tiempo: antepartum (expected average 7 months) and within first 3 months postpartum
|
Other complications sufficient to stop treatment (e.g., local and systemic reactions) antepartum and within first 3 months postpartum
|
antepartum (expected average 7 months) and within first 3 months postpartum
|
Pregnancy complications and outcomes
Periodo de tiempo: antepartum period (expected average 7 months)
|
Pregnancy complications and outcomes including fetal death, pre-eclampsia, toxemia, intrauterine growth restriction, prematurity during antepartum period
|
antepartum period (expected average 7 months)
|
Fetal anomalies
Periodo de tiempo: antepartum (expected average 7 months) and during first 3 months postpartum
|
Fetal anomalies
|
antepartum (expected average 7 months) and during first 3 months postpartum
|
Major and minor bleeding
Periodo de tiempo: antepartum (expected average 7 months)
|
Major and minor bleeding
|
antepartum (expected average 7 months)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Shannon M Bates, MD, McMaster University Medical Centre
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- tromboembolismo
- enfermedades cardiovasculares
- anticoagulantes
- trombosis venosa
- Tromboembolismo venoso
- La trombosis venosa profunda
- embolia pulmonar
- trombosis
- enoxaparina
- tromboprofilaxis
- agentes cardiovasculares
- enfermedades vasculares
- tinzaparina
- dalteparina
- complicaciones del embarazo
- embolia y trombosis
- hematologic agents
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HHS130511
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .